As many as 241 blood cancer medications are in clinical testing or are being considered by the FDA, a report from PhRMA has found. Ninety-eight are potential lymphoma treatments, while 97 are for leukemia and 52 for multiple myeloma. These drugs "reflect biopharmaceutical research companies' commitment to build on progress to date and help bring new treatment options to patients," PhRMA President and CEO John J. Castellani said.

Full Story:
Drug Store News

Related Summaries